CoChat

Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

AIM: The impact of paravalvular regurgitation (PVR) following transcatheter aortic valve replacement (TAVR) remains uncertain. In this analysis, we sought to evaluate the impact of varying degrees of PVR on both mortality and changes in ventricular geometry and function. METHODS AND RESULTS: Clinical and echocardiographic outcomes of patients who underwent TAVR from the randomized cohorts and continued access registries in the PARTNER trial were analysed after stratifying by severity of post-implant PVR, which was graded as none/trace in 52.9% (n = 1288), mild in 38.0% (n = 925), and moderate/severe in 9.1% (n = 221). There were significant differences in baseline clinical and echocardiographic characteristics. After TAVR, all the patients demonstrated increase in left ventricular (LV) function and reduction in the LV mass index, although the magnitude of mass regression was lower in the moderate/severe PVR group. The 30-day mortality (3.1 vs. 3.4 vs. 4.5%, P = 0.56) and stroke (3.4 vs. 3.7 vs. 2.3%, P = 0.59) were similar in all groups (none/trace, mild, and moderate/severe). At 1 year, there was increased all-cause mortality (15.9 vs. 22.2 vs. 35.1%, P < 0.0001), cardiac mortality (6.1 vs. 7.4% vs. 16.3%, P < 0.0001) and re-hospitalization (14.4 vs. 23.0 vs. 31.3%, P < 0.0001) with worsening PVR. A multivariable analysis indicated that the presence of moderate/severe PVR (HR: 2.18, 95% CI: 1.57-3.02, P < 0.0001) or mild PVR (HR: 1.37, 95% CI: 1.14-1.90, P = 0.012) was associated with higher late mortality. CONCLUSION: Differences in baseline characteristics in patients with increasing severities of PVR may increase the risk of this complication. Despite these differences, multivariable analysis demonstrated that both mild and moderate/severe PVR predicted higher 1-year mortality.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu384

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. 2012, New England Journal of Medicine, 366, 1686, 10.1056/nejmoa1200384 · DOI · Paper page

Cited by

See all 476

Metadata

Authors
Kodali, S., Pibarot, P., Douglas, P. S., Williams, M., Xu, K., Thourani, V., Rihal, C. S., Zajarias, A., Doshi, D., Davidson, M., Tuzcu, E. M., Stewart, W., Weissman, N. J., Svensson, L., Greason, K., Maniar, H., Mack, M., Anwaruddin, S., Leon, M. B., & Hahn, R. T.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Duke Clinical Research Institute (US)
  • Cardiovascular Research Foundation (US)
  • Emory University (US)
  • Mayo Clinic (US)
  • Brigham and Women's Hospital (US)
  • Cleveland Clinic (US)
  • MedStar Health Research Institute (US)
  • Washington University in St. Louis (US)
  • Hospital of the University of Pennsylvania (US)
Corresponding author
Kodali, S.
Venue
European Heart Journal
Published
2014-10-01
Volume
36
Issue
7
Pages
449-456
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2081463532
Cited by
446
References
40
Citations by year
2026: 14 · 2025: 18 · 2024: 17 · 2023: 29 · 2022: 33 · 2021: 31 · 2020: 48 · 2019: 45 · 2018: 49 · 2017: 67 · 2016: 60 · 2015: 31 · 2014: 3
FWCI
36.78
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Corpus Université Laval (Université Laval) (submittedVersion)
Funders
Edwards Lifesciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
paravalvular leak, transcatheter aortic valve implantation, Edwards SAPIEN valve, PARTNER trial, aortic stenosis, mortality, left ventricular mass, ventricular geometry, hospital readmission, stroke, echocardiographic assessment, risk stratification, transcatheter versus surgical aortic valve replacement, left ventricular function
MeSH terms
Aged, 80 and over, Aortic Valve Insufficiency, Aortic Valve Stenosis, Echocardiography, Female, Humans, Male, Mitral Valve Insufficiency, Organ Size, Reoperation, Heart Valve Prolapse, Treatment Outcome, Transcatheter Aortic Valve Replacement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. https://app.cochat.ai/papers/10.1093/eurheartj/ehu384
The paper
Kodali, S., Pibarot, P., Douglas, P. S., Williams, M., Xu, K., Thourani, V., Rihal, C. S., Zajarias, A., Doshi, D., Davidson, M., Tuzcu, E. M., Stewart, W., Weissman, N. J., Svensson, L., Greason, K., Maniar, H., Mack, M., Anwaruddin, S., Leon, M. B., & Hahn, R. T. (2015). Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu384

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.